As used in this subchapter:
(1) “Eligible patient” means a person who meets the requirements of eligibility in § 20-15-2104;
(2) “Investigational drug, biological product, or device” means a drug, biological product, or device that: Has successfully completed phase I of clinical trials but has not been approved for general use by the United States Food and Drug Administration; and
(3) Remains currently under investigation in a United States Food and Drug Administration clinical trial;
(4) “Physician” means an individual licensed to practice medicine in the State of Arkansas under the Arkansas Medical Practices Act, § 17-95-201 et seq., § 17-95-301 et seq., and § 17-95-401 et seq.; and
(5) “Terminal illness” means an incurable and irreversible condition that without the administration of life-sustaining treatment will, in the opinion of the patient's physician, result in death within a relatively short time.